SCHEMBL315415

SCHEMBL315415

[CH2]c1cc(C)no1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5728 0.71
Formaldehyde SCHEMBL27843442 0.70
SCHEMBL1233711 0.69
Ammonia Solution, Strong SCHEMBL7395872 0.69
SCHEMBL6966897 0.67
SCHEMBL2373943 0.67
SCHEMBL2310979 0.67
SCHEMBL4086630 0.67
SCHEMBL8868767 0.67
SCHEMBL7043489 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111542526-B Condensed imidazole derivatives substituted with tertiary hydroxyl groups as PI 3K-gamma inhibitors 因赛特公司 2024-01-09 CN claimed
EP-4273147-A1 SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES Bayer Aktiengesellschaft (DE) 2023-11-08 EP claimed
CN-113004278-B Bicyclic heterocycles as FGFR inhibitors 因赛特控股公司 2023-07-21 CN claimed
CN-116196307-A Methods for treating disorders involving positive regulation of CD47, methods for increasing phagocytosis of cells, and pharmaceutical compositions 台湾卫生研究院 2023-06-02 CN claimed
US-20230097801-A1 METHODS OF INCREASING CELL PHAGOCYTOSIS NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2023-03-30 US claimed
EP-4151207-A1 BENZIMIDAZOLES FOR USE IN THE TREATMENT OF CONDITIONS INVOLVING CD47 UPREGULATION OR FOR INCREASING PHAGOCYTOSIS OF A CELL National Health Research Institutes (TW) 2023-03-22 EP claimed
EP-3965884-A1 MODULATORS OF THR-BETA AND METHODS OF USE THEREOF Aligos Therapeutics, Inc. (US) 2022-03-16 EP claimed
CN-114096531-A THR-beta modulators and methods of use thereof 阿利戈斯治疗公司 2022-02-25 CN claimed
US-11225486-B2 Tertiary alcohols as PI3K-γ inhibitors INCYTE CORPORATION (US) 2022-01-18 US claimed
EP-3421457-B1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MAN CO LTD (JP) 2021-10-06 EP claimed
EP-1954137-A2 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-08-13 EP claimed
US-7247748-B2 Amide compounds and methods of using the same SMITHKLINE CORPORATION (US) 2007-07-24 US claimed
WO-2007061862-A2 2-KETO-OXAZOLES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-31 WO claimed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO claimed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US claimed
JP-2006514925-A 2006-05-18 JP claimed
EP-1497270-A4 AMIDE COMPOUNDS AND METHODS OF USING THE SAME SMITHKLINE BEECHAM CORP (US) 2006-01-04 EP claimed
US-20050107444-A1 Amide compounds and methods of using the same GLAXOSMITHKLINE LLC 2005-05-19 US claimed
EP-1497270-A1 AMIDE COMPOUNDS AND METHODS OF USING THE SAME SmithKline Beecham Corporation (US) 2005-01-19 EP claimed
WO-2004043939-A1 AMIDE COMPOUNDS AND METHODS OF USING THE SAME SMITHKLINE BEECHAM CORPORATION (US) 2004-05-27 WO claimed